New product insight

CHO cell lines expressing Fcγ receptors – an in vitro tool for antibody based drug discovery

New CHO cell line variants, expressing different classes of Fc gamma receptors (FcγRs) have been deposited exclusively into the ECACC General Collection by Cambridge Enterprise Limited, UK. The variant lines were developed in the laboratory of Dr. Mike Clark at Cambridge University and include five cell lines that express three different human FcγRs including allotypes of FcγRIIa and FcγRIIIa (Table 1)^1,2.

Table 1:ECACC exclusive CHO variant cell lines expressing human Fc gamma receptors

The Fcγ receptor family are expressed on the surface of hematopoietic cells and are involved in regulating immune responses through activating or inhibitory signals³. The Fc domains of the four subclasses of immunoglobulin G (IgG1, IgG2, IgG3 and IgG4) bind to FcγRs with varying affinities (Table 2). Formation of Fc-FcγR complexes initiates a number of immunological responses including antibody dependent cell mediated cytotoxicity and phagocytosis^4,5.

Table 2: Human Fc gamma receptor expression in hematopoietic cells³

Antibody based therapies are used to treat a number of cancers and autoimmune diseases and their effectiveness, in part, depends on the binding affinity of IgG antibodies and FcγRs.  Polymorphisms in the genes encoding for the FcγRs can affect a patient’s response to antibody and immunoglobulin therapy.  Examples of such variances in individual responses have been reported in the literature. Treatment of non-Hodgkin lymphomas with Rituximab has been shown to be more effective in homozygous FCGR3A-158V patients compared with heterozygous FCGR3A-158F carriers⁶. In addition, FCGR gene polymorphisms have also been identified as a risk factor for a number of immunological diseases (Table 3). Thus, FcγRs influence both disease progression and therapeutic response in patients. 

Table 3: Diseases associated with Fc gamma receptor polymorphisms⁷

Fc gamma receptors are proving to be useful targets for the treatment of autoimmune diseases and cancer. Understanding the biophysical interactions between the receptors and IgG antibodies is aiding the development of more personalised and effective therapies. The FcγR expressing CHO cell lines from ECACC offer researchers a novel easy to access in vitro model for better understanding of receptor function and provide a novel tool for use in antibody-based drug discovery and development.

References

1. Armour, K. L., et al., (2010) Expression of human FcγRIIIa as a GPI-linked molecule on CHO cells to enable measurement of human IgG binding. Journal of Immunological Methods 354, 20-33
2. Armour, K. L., et al., (2014) Low-affinity FcγR interactions can decide the fate of novel human IgG-sensitised red blood cells and platelets. European Journal of Immunology 44, 905-914
3. Levin, D., et al., (2015) Fc fusion as a platform technology: potential for modulating immunogenicity.  Trends in Biotechnology 33, 27-34
4. Nimmerjahn, F. and Ravetch, J. V., (2008) Fcγ receptors as regulators of immune responses. Nature Reviews Immunology 8, 34-47
5. Irani, V., et al., (2015) Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases. Molecular Immunology 67, 171-182
6. Cartron, G., et al., (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood Journal 99, 754-758
7. Gillis, C., et al., (2014) Contribution of human FcγRs to disease with evidence from human polymorphisms and transgenic animal studies. Frontiers in Immunology  5, 254

February 2017